Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.

Journal of Cellular and Molecular Medicine
Marianne SkeieEspen Stang

Abstract

The receptor tyrosine kinase HER2 is associated with a number of human malignancies and is an important therapeutic target. The antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla® ) is recommended as a first-line treatment for patients with HER2-positive metastatic breast cancer. T-DM1 combines the antibody-induced effects of the anti-HER2 antibody trastuzumab (Herceptin® ) with the cytotoxic effect of the tubulin inhibitor mertansine (DM1). For DM1 to have effect, the T-DM1-HER2 complex has to be internalized and the trastuzumab part of T-DM1 has to be degraded. HER2 is, however, considered endocytosis-resistant. As a result of this, trastuzumab is only internalized to a highly limited extent, and if internalized, it is rapidly recycled. The exact reasons for the endocytosis resistance of HER2 are not clear, but it is stabilized by heat-shock protein 90 (Hsp90) and Hsp90 inhibitors induce internalization and degradation of HER2. HER2 can also be internalized upon activation of protein kinase C, and contrary to trastuzumab alone, the combination of two or more anti-HER2 antibodies can induce efficient internalization and degradation of HER2. With intention to find ways to improve the action of T-DM1, we investigated ...Continue Reading

References

Feb 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tsipi Ben-KasusMichael Sela
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHoward A Burris
Aug 8, 2014·Membranes·Vibeke Bertelsen, Espen Stang
Jan 24, 2015·Molecular Cancer Therapeutics·Mikkel W PedersenMichael Kragh
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group
Jul 30, 2016·Journal of Cellular and Molecular Medicine·Monika SzymanskaVibeke Bertelsen
Apr 2, 2019·Current Treatment Options in Oncology·Noam PondéMartine Piccart
Sep 4, 2019·Lancet·Cindy H ChauWilliam D Figg
Sep 25, 2019·Nature Reviews. Clinical Oncology·Do-Youn Oh, Yung-Jue Bang

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PMA

Software Mentioned

CLEOPATRA
MARIANNE

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.